• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic touts cryoablation therapy study results

Medtronic touts cryoablation therapy study results

September 3, 2020 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) touted results demonstrating the superiority of two of its cryoablation therapy technologies.

Fridley, Minn.-based Medtronic said in a news release that trials showed the superiority of the Arctic Front advance cardiac cryoballoon and the Freezor max cardiac cryoablation catheter for the first-line treatment (before drug therapy) of recurrent symptomatic paroxysmal atrial fibrillation (PAF) when compared to antiarrhythmic drug (AAD) treatment.

The company presented the primary results from the randomized STOP-AF first trial at the 2020 European Society of Cardiology (ESC) Congress and noted that 12-month outcomes from the Cryo-First trial showed significant improvements in atrial fibrillation-related quality of life with the use of Medtronic’s cryoablation system compared to anti-arrhythmic drug therapy in patients who hadn’t previously received anti-arrhythmic drugs to treat their symptomatic PAF.

STOP-AF enrolled 225 patients across 24 U.S. sites, with 203 randomized to cryoablation (104 in treatment arm) or AAD therapy (99 in control arm). They received treatment and were followed for 12 months, after which results showed that cryoablation had treatment success in 75% of patients in the catheter ablation group compared to 45% in the AAD group.

Cryo-First enrolled 220 patients at 18 sites across nine countries in Europe, Australia and Latin America. Medtronic observed that its cryoablation solution resulted in a significant improvement in AF-specific, health-related quality of life at 12 months compared to AAD therapy.

Medtronic’s Arctic Front advance cryoablation system is approved in Europe for treating AF, while the FDA recently expanded the indication for it to include treating patients with symptomatic, recurrent persistent AF. Results of the STOP-AF first trial have not been reviewed by the FDA, Medtronic said.

“More than half of patients with symptomatic AF do not experience a reduction in AF with antiarrhythmic drugs, effectively delaying their therapy and leaving a critical need for an alternative first-line treatment,” Medtronic chief medical officer of the cardiac rhythm & heart failure & cardiac ablation solutions divisions Dr. Rob Kowal said in the release. “Not only do the STOP AF First findings show cryoablation is a potential first-line treatment for these patients, the Cryo-FIRST results show encouraging benefits of this treatment approach on these patients’ quality of life.”

Filed Under: Cardiovascular, Catheters, Clinical Trials Tagged With: Medtronic

More recent news

  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Medtronic issues safety notice for Hugo surgical robot console in Europe

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy